Pantoprazol Hikma (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Hikma, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazol Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Hikma is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions:

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: heals erosions and reduces further damage caused by acid exposure. - Peptic ulcer disease: supports ulcer healing and helps prevent recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the disorder. - Helicobacter pylori eradication regimens (as adjunct): enhances ulcer healing when used with antibiotics.

Pantoprazol Hikma may cause unwanted reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools that usually resolve without treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent diarrhoea with abdominal cramping. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Liver enzyme elevation: abnormal blood test results indicating hepatic stress. - Fracture risk with long‑term use: decreased bone mineral density. - Acute interstitial nephritis: kidney inflammation presenting with fever and flank pain.

When prescribing Pantoprazol Hikma, clinicians should consider several safety aspects:

- Assess renal function: adjust use in patients with severe kidney impairment. - Review hepatic status: use cautiously in moderate to severe liver disease. - Monitor electrolytes: watch for low magnesium during prolonged therapy. - Evaluate infection risk: prolonged acid suppression may increase susceptibility to gastrointestinal infections. - Consider bone health: assess fracture risk in long‑term users, especially the elderly. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole can affect the plasma concentrations of several co‑administered medicines. Understanding the interaction potential helps optimise therapy.

Major Interactions (Avoid): - Antifungal agents (e.g., itraconazole, ketoconazole): reduced absorption and efficacy. - HIV protease inhibitors (e.g., atazanavir, nelfinavir): markedly decreased plasma levels. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Methotrexate: reduced renal clearance may raise toxicity risk. - Digoxin: slight increase in serum concentrations. - Oral contraceptives: potential decrease in hormonal efficacy. - Phenytoin: altered plasma levels, necessitating dosage adjustment.